May 20, 2008 - Basilea Pharmaceutica Ltd. (SWX: BSLN) highlights the presentation of positive phase III results on ceftobiprole in the treatment of community-acquired pneumonia (CAP) requiring hospitalization at the International Conference of the American Thoracic Society (ATS). The detailed analysis of previously announced top line results demonstrate high cure rates in patients at risk for poor outcomes. The randomized, double-blind phase III study compared clinical outcomes following the treatment with ceftobiprole versus ceftriaxone with or without linezolid in patients hospitalized with community-acquired pneumonia. The clinical cure rate in the clinically evaluable patient population with moderate to severe pneumonia was 87% for ceftobiprole and 88% for the comparator arm. In patients infected with Streptococcus pneumoniae, the most common pathogen in CAP, high cure rates were achieved with ceftobiprole (93%) and the comparator (89%). In the overall study population ceftobiprole met non-inferiority with a margin (delta) of 10%... Basilea Pharmaceutica's Press Release -
